Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
21.30
Sep 21 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
972.37M
Enterprise Value
1.12B
Income
-
Sales
-
Book/sh
-3.19
Cash/sh
2.52
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Aug 05, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
8.45
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
9.39
Current Ratio
9.39
Debt/Eq
0.04
LT Debt/Eq
0.02
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-0.56
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Insider Own
37.77%
Insider Trans
19.63%
Inst Own
15.65%
Inst Trans
9.99%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-4.62%
SMA50
-1.52%
SMA200
-1.52%
Trades
Shs Outstand
45.65M
Shs Float
28.41M
52W High
28.00 -23.93%
52W Low
16.15 31.89%
Volatility
11.71% 11.35%
ATR (14)
2.54
RSI (14)
45.38
Beta
-
Rel Volume
0.00
Avg Volume
435.89K
Volume
0
Perf Week
-13.13%
Perf Month
5.39%
Perf Quarter
-
Perf Half Y
-
Perf YTD
1.43%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
21.30
Price
21.30
Change %
0.00%
Date Action Analyst Rating Change Price Target Change
Aug-31-26Initiated RBC Capital Mkts Outperform $45
Aug-31-26Initiated Morgan Stanley Overweight $39
Aug-31-26Initiated Leerink Partners Outperform $52
Aug-31-26Initiated Citigroup Buy $30
Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that creates next-generation biologic medicines for immune-mediated diseases. It was founded in 2022 and is headquartered in San Carlos, CA.
M.S.Mr. Tao Fu M.B.A.
Chief Scientific OfficerDr. Petter Veiby Ph.D.
M.P.H.Dr. Hubert C. Chen M.D.
Chief Financial OfficerMr. Steven Chan CPA
Chief Technology OfficerDr. Hangjun Zhan Ph.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDMAN SACHS GROUP INCFormer 10% OwnerAug 05 '26Proposed Sale21.00105,8072,221,947Aug 28 05:50 PM
WALSH COLINDirectorAug 06 '26Buy17.00500,0008,500,0003,020,632Aug 13 09:52 PM
WALSH COLINDirectorAug 05 '26Buy21.0085,0001,785,00085,000Aug 13 09:52 PM
WALSH COLINDirectorAug 05 '26Sale21.28105,8072,251,6580Aug 13 09:52 PM
GOLDMAN SACHS GROUP INCFormer 10% OwnerAug 06 '26Buy17.00500,0008,500,0003,020,632Aug 13 09:51 PM
GOLDMAN SACHS GROUP INCFormer 10% OwnerAug 05 '26Buy21.0085,0001,785,00085,000Aug 13 09:51 PM
GOLDMAN SACHS GROUP INCFormer 10% OwnerAug 05 '26Sale21.28105,8072,251,6580Aug 13 09:51 PM
venBio Global Strategic Fund I10% OwnerAug 06 '26Buy17.00382,3526,499,9844,181,367Aug 10 04:12 PM
Redmile Group, LLC10% OwnerAug 06 '26Buy17.00400,0006,800,0001,182,854Aug 07 09:47 PM
Redmile Group, LLC10% OwnerAug 06 '26Buy17.00200,0003,400,000982,854Aug 07 09:47 PM
Sanofi10% OwnerAug 06 '26Buy17.00300,0005,100,0001,082,855Aug 07 03:45 PM
Frazier Life Sciences XI, L.P.10% OwnerAug 06 '26Buy17.00588,2359,999,9956,154,213Aug 06 05:35 PM